{"analyses":[{"ciLowerLimit":"0.67","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.93","groupIds":["OG000","OG002"],"nonInferiorityType":"SUPERIORITY","paramType":"Hazard Ratio (HR)","paramValue":"0.79"},{"ciLowerLimit":"0.81","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.12","groupIds":["OG001","OG002"],"nonInferiorityType":"SUPERIORITY","paramType":"Hazard Ratio (HR)","paramValue":"0.95"},{"ciLowerLimit":"0.72","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.99","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","paramType":"Hazard Ratio (HR)","paramValue":"0.85"},{"ciLowerLimit":"0.60","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.97","groupIds":["OG003","OG005"],"nonInferiorityType":"SUPERIORITY","paramType":"Cox Proportional Hazard","paramValue":"0.76"},{"ciLowerLimit":"0.59","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.93","groupIds":["OG004","OG005"],"nonInferiorityType":"SUPERIORITY","paramType":"Hazard Ratio (HR)","paramValue":"0.74"},{"ciLowerLimit":"0.52","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.72","groupIds":["OG006","OG007"],"nonInferiorityType":"SUPERIORITY","paramType":"Hazard Ratio (HR)","paramValue":"0.61"},{"ciLowerLimit":"0.49","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.89","groupIds":["OG008","OG009"],"nonInferiorityType":"SUPERIORITY","paramType":"Hazard Ratio (HR)","paramValue":"0.66"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"4.07","upperLimit":"6.31","value":"5.06"},{"groupId":"OG001","lowerLimit":"3.22","upperLimit":"5.32","value":"4.17"},{"groupId":"OG002","lowerLimit":"4.63","upperLimit":"5.82","value":"5.55"},{"groupId":"OG003","lowerLimit":"3.15","upperLimit":"6.28","value":"4.90"},{"groupId":"OG004","lowerLimit":"4.63","upperLimit":"6.90","value":"5.55"},{"groupId":"OG005","lowerLimit":"4.21","upperLimit":"5.59","value":"4.70"},{"groupId":"OG006","lowerLimit":"7.10","upperLimit":"9.59","value":"8.34"},{"groupId":"OG007","lowerLimit":"4.47","upperLimit":"5.85","value":"5.52"},{"groupId":"OG008","lowerLimit":"4.14","upperLimit":"8.34","value":"5.78"},{"groupId":"OG009","lowerLimit":"4.37","upperLimit":"6.77","value":"5.49"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"396"},{"groupId":"OG001","value":"396"},{"groupId":"OG002","value":"397"},{"groupId":"OG003","value":"187"},{"groupId":"OG004","value":"177"},{"groupId":"OG005","value":"186"},{"groupId":"OG006","value":"377"},{"groupId":"OG007","value":"378"},{"groupId":"OG008","value":"126"},{"groupId":"OG009","value":"127"}],"units":"Participants"}],"description":"Progression-Free Survival then (PFS) is defined as the time between the date of randomization and the date of first documented disease progression, based on BICR assessments (per RECIST v1.1), or death due to any cause, whichever occurs first based on Kaplan-Meier estimates. Progressive Disease (PD): At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum during the study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants with PD-L1 positive status Non Small Cell Lung Cancer received nivolumab 3 mg/kg IV over 30 minutes Q2W + ipilimumab 1 mg/kg over 30minutes every 6 weeks (Q6W) given for up to 24 months in the absence of disease progression or unacceptable toxicity.","id":"OG000","title":"Part 1-Arm B: Nivo + Ipi"},{"description":"Participants with PD-L1 positive status Non Small Cell Lung Cancer received nivolumab 240 mg intravenously (IV) over 30 minutes every 2 weeks (Q2W) given for up to 24months in the absence of disease progression or unacceptable toxicity.","id":"OG001","title":"Part 1-Arm A: Nivolumab"},{"description":"Participants with PD-L1 positive status Non Small Cell Lung Cancer received histology-based platinum-doublet chemotherapy IV in3-week cycles for a maximum of 4 cycles or until disease progression or unacceptable toxicity (whichever comes first). For participants with NSQ histology, pemetrexed maintenance was allowed until disease progression or unacceptable toxicity after 4 cycles of chemotherapy.","id":"OG002","title":"Part 1-Arm C: Chemotherapy"},{"description":"Participants with PD-L1 negative status Non Small Cell Lung Cancer received nivolumab 3 mg/kg IV over 30 minutes Q2W + ipilimumab 1 mg/kg over 30minutes Q6W given for up to 24 months in the absence of disease progression or unacceptable toxicity.","id":"OG003","title":"Part 1-Arm D: Nivo + Ipi"},{"description":"Participants with PD-L1 negative status Non Small Cell Lung Cancer received nivolumab 360 mg IV over 30 minutes combined with platinum-doublet chemotherapy administered IV every 3 weeks for a maximum of 4 cycles. Participants who have not experienced disease progression were to receive nivolumab 360 mg every 3weeks until the progression of disease, discontinuation due to toxicity, or up to 24 months (whichever comes first). For subjects with NSQ histology, pemetrexed maintenance was allowed until disease progression or unacceptable toxicity after 4 cycles of chemotherapy.","id":"OG004","title":"Part 1-Arm G: Nivo + Chemo"},{"description":"Participants with PD-L1 negative status Non Small Cell Lung Cancer received histology-based platinum-doublet chemotherapy IV in 3-week cycles for a maximum of 4 cycles or until disease progression or unacceptable toxicity (whichever comes first). For participants with NSQ histology, pemetrexed maintenance was allowed until disease progression or unacceptable toxicity after 4 cycles of chemotherapy.","id":"OG005","title":"Part 1-Arm F: Chemotherapy"},{"description":"Chemotherapy-naive participants with stage IV or recurrent NSCLC irrespective of PD-L1 expressing levels received nivolumab 360 mg IV over 30 minutes combined with platinum-doublet chemotherapy administered IV every 3 weeks for a maximum of 4 cycles. Participants who have not experienced disease progression were to receive nivolumab 360 mg every 3weeks until the progression of disease, discontinuation due to toxicity, or up to 24 months (whichever comes first). For subjects with NSQ histology, pemetrexed maintenance was allowed until disease progression or unacceptable toxicity after 4 cycles of chemotherapy.","id":"OG006","title":"Part 2 - Arm H: Nivolumab + Chemotherapy"},{"description":"Chemotherapy-naive participants with stage IV or recurrent NSCLC irrespective of PD-L1 expressing levels received histology-based platinum-doublet chemotherapy IV in 3-week cycles for a maximum of 4 cycles or until disease progression or unacceptable toxicity (whichever comes first). For participants with NSQ histology, pemetrexed maintenance was allowed until disease progression or unacceptable toxicity after 4 cycles of chemotherapy.","id":"OG007","title":"Part 2 - Arm I: Chemotherapy"},{"description":"Participants in China with PD-L1 Non Small Cell Lung Cancer received nivolumab 3 mg/kg IV over 30 minutes Q2W + ipilimumab 1 mg/kg over 30minutes every 6 weeks (Q6W) given for up to 24 months in the absence of disease progression or unacceptable toxicity.","id":"OG008","title":"Part 3 -Arm J: Nivolumab + Ipilimumab"},{"description":"Participants in China with PD-L1 Non Small Cell Lung Cancer received histology-based platinum-doublet chemotherapy IV in3-week cycles for a maximum of 4 cycles or until disease progression or unacceptable toxicity (whichever comes first). For participants with NSQ histology, pemetrexed maintenance was allowed until disease progression or unacceptable toxicity after 4 cycles of chemotherapy.","id":"OG009","title":"Part 3 - Arm K: Chemotherapy"}],"paramType":"MEDIAN","populationDescription":"All randomized participants","reportingStatus":"POSTED","timeFrame":"From randomization untill disease progression or death, whichever occurs first (up to approximately 481 weeks)","title":"Progression-Free Survival Per BICR","type":"PRIMARY","unitOfMeasure":"months"}